Year-end Sale % OFF 
Abstract
Early adoption of extracorporeal membrane oxygenation (ECMO) for the management of refractory respiratory and cardiopulmonary failure associated with coronavirus disease 2019 (COVID-19) has resulted in a growing use of this highly technical modality. The prothrombotic state associated with severe COVID-19 presents unique challenges to management. In the setting of ECMO, characterized by large-cannula instrumentation, patients with both arterial and venous thrombosis may be recalcitrant to traditional anticoagulation therapy requiring expertise of vascular subspecialists for diagnosis and management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
